Bristol-Myers Squibb Canada wishes to advise you of a shortage of Canadian labeled BiCNU (carmustine for injection U.S.P.) Lyophilized Powder, 100 mg/vial (DIN 00297763). In Canada, BiCNU (carmustine) is indicated as palliative therapy to surgery and radiotherapy or in combination therapy with other chemotherapeutic agents in primary brain tumors, malignant lymphomas, multiple myeloma, malignant melanoma (disseminated) and gastrointestinal carcinoma. Read more
here.
No comments:
Post a Comment